belrestotug

News

GSK pays $1.2bn for liver drug as it culls TIGIT programme

GSK decided to abandon a TIGIT-targeted drug for cancer this week, then hatched a plan to replace it with a candidate for liver disease MASH.

News

ESMO: GSK, iTeos bring some optimism back to TIGIT

GSK and iTeos anti-TIGIT antibody belrestotug showed efficacy in a phase 2 trial in PD-L1-positive non-small cell lung cancer (NSCLC), providing some much-needed positive news for the belea

News

Jasper and Kira merge to build immune-focused biotech

Faced with the prospect of running out of cash, Jasper Therapeutics has merged with Kira Pharma, fortified by $132m in new private funding.

/themes/custom/pharmaphorum_theme/library/img/article-label-image/ondemand.png

Digital

Discover a new era of healthcare panel engagement: Grounded ...

A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.

Editor's Picks